Background-Current guidelines do not provide recommendations for optimal timing of coronary artery bypass surgery (CABG) in patients with non-ST-segment-elevation myocardial infarction. Our study aimed to determine the impact of CABG timing on early and late outcomes in patients with non-ST-segment-elevation myocardial infarction. Methods and Results-A total of 758 patients underwent CABG within 21 days after non-ST-segment-elevation myocardial infarction between January 2008 and December 2012 at our institution. The patients were divided into 3 groups according to the time interval between symptom onset and CABG: group A, <24 hours (133 patients); group B, 24 to 72 hours (192 patients); and group C, >72 hours to 21 days (433 patients). Predictors of in-hospital and long-term mortality were identified by logistic and Cox regression analyses, respectively. Overall in-hospital mortality was 5.1% (39 patients): 6.0%, 4.7%, and 5.1% in groups A, B, and C (P=0.9), respectively. A total of 118 patients died during follow-up. The 5-year survival was 73.1±2%, with a nonsignificant trend toward better survival in groups A (78.2±4%) and C (75.4±3%) compared with group B (63.6±5%; log-rank P=0.06). Renal insufficiency and LMD were independent predictors of in-hospital (odds ratio, 3.1; P=0.001; and odds ratio, 3.1; P=0.002) and long-term mortality (hazard ratio, 1.7; P=0.004; and hazard ratio, 1.5; P=0.02), whereas administration of P2Y 12 inhibitors was protective (odds ratio, 0.3; P=0.01). Conclusions-Emergent CABG within 24 hours of non-ST-segment-elevation myocardial infarction is associated with in-hospital mortality and long-term outcomes similar to those of CABG performed after 3 days, despite a higher risk profile. CABG performed between 24 to 72 hours showed a nonsignificant trend toward poorer long-term outcomes. Dual antiplatelet therapy until surgery is beneficial, whereas renal insufficiency and left main disease increase the risk of early and late death. (Circulation. 2015;132:731-740.
T he management of patients with non-ST-segment-elevation myocardial infarction (NSTEMI) involves either a routine invasive therapy or an ischemia-guided therapy. Nevertheless, the long-lasting beneficial effects of early intervention should be weighed against the higher risk of procedure-related complications and deaths. Several meta-analyses that included contemporary randomized, controlled trials (RCTs) have shown a substantial risk reduction in all-cause mortality and myocardial infarction (MI) at 1 to 2 years after an early invasive strategy, 1,2 particularly in patients with the highest risk profile. 3 The treatment of choice, whether percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), is based on the same considerations used for patients with stable coronary artery disease. 4 Approximately 7% to 13% of patients hospitalized with NSTEMI undergo in-hospital CABG, 5, 6 about a third performed within 48 hours of hospital admission. 5 Several studies investigating the impact of timing of CABG on in-hospital and short-term outcomes in NSTEMI have produced conflicting results, with some favoring a waiting period of 3 to 5 days 7 as a result of lower in-hospital mortality (HM) with an increasing time interval between CABG and MI. 8 Conversely, others claim that patients with NSTEMI may undergo CABG surgery at any time with outcomes similar to those of patients without MI, 9 and delaying CABG routinely after NSTEMI increases resource use without improving outcomes. 6 To the best of our knowledge, very few publications on surgical treatment of NSTEMI exist in literature, especially in the last decade, with no contemporary long-term outcome data. As a result of the lack of convincing evidence, the optimal timing of CABG after NSTEMI was not addressed in the recently published American College of Cardiology/American Heart Association guidelines for non-ST-segment-elevation acute coronary syndrome (NSTE-ACS). 10 The main objective of our study was to determine the effect of the time interval between the onset of NSTEMI and CABG on in-hospital and long-term outcomes and thus to identify the most favorable time period in which to perform the operation.
Methods

Data Source
During the 5-year period between January 2008 and December 2012, 4610 consecutive patients underwent isolated CABG at the Leipzig Heart Center. Of these, 2037 patients had suffered a MI before surgery, of whom 989 were operated on within 21 days after acute MI. A total of 758 patients had NSTEMIs and 231 had STEMIs. The present study involves a comprehensive analysis of the former group of patients. Patients undergoing concomitant cardiac procedures such as repair of mechanical complications of MI or valvular, aortic, or vascular surgery were excluded from the analysis. Patient charts were reviewed to confirm the diagnosis of NSTEMI and to retrieve relevant laboratory data, the exact times of symptom onset and CABG, and the indication for surgery. Baseline characteristics, including the demographic profile, cardiac risk factors, other comorbidities, preoperative hemodynamic status, and medications, were obtained from a prospectively entered computerized database. The intraoperative details and postoperative mortality and morbidity data also were recorded.
The study was approved by our Institutional Ethics Committee. Because this was a retrospective study, individual patient informed consent was waived.
Definitions
Patients presenting with persistent or transient ST-segment depression or T-wave inversion, flat T waves, or pseudonormalization of T waves and those with no ECG changes at presentation with elevation in troponin and/or creatine kinase (CK)-MB levels above normal values were considered to have NSTEMI. 11 Renal insufficiency was graded according to creatinine clearance (grade 1, >90 mL·min ). 12 Presence of cardiogenic shock was prospectively entered into our database for every patient at the time of surgery on the basis of the following: systolic blood pressure <90 mm Hg for at least 30 minutes, the need for inotropes/intra-aortic balloon pump to maintain a systolic blood pressure>90 mm Hg or inadequate peripheral perfusion (cool extremities or urine output <30 mL/h), a heart rate of >90 bpm, or the need for cardiopulmonary resuscitation.
Patient Groups
There is a lack of standardized timing intervals for the performance of CABG after NSTEMI. Two treatment strategies that have emerged for patients with NSTEMI with respect to invasive diagnosis and intervention are early invasive (within 24 hours) and delayed invasive (25-72 hours). 10 We therefore created 3 groups based on the time interval between symptom onset and start of surgery. Patients were operated on within 24 hours after symptom onset (group A), between 24 to 72 hours after symptom onset (group B), and after 72 hours after symptom onset (group C).
The rationale for using these time intervals was to maintain consistency in the time intervals used by cardiologists, who most frequently decide the course and type of therapy for these patients. Because the decision on the type of therapy in terms of early or delayed invasive is made before the patient is referred to the cardiac surgeon, we thought it prudent to use these same time intervals to further evaluate the results of CABG. Furthermore, patients operated on after 72 hours of NSTEMI are usually stable and form a good baseline group for comparison with the other 2 groups. Additionally, using a minimum duration of 24 hours after NSTEMI is realistic in daily practice because very few patients reach the operating table within the so-called 6-hour golden period after MI.
Of the 758 patients with NSTEMI, 43 had developed cardiogenic shock before surgery. It is a known fact that patients in cardiogenic shock (shock patients) require emergency revascularization regardless of the time duration after acute MI (Class 1A recommendation). 4, 13 However, no consensus exists on the ideal timing of CABG in patients with NSTEMI without cardiogenic shock. Therefore, the complete analysis was also performed after exclusion of these patients (online-only Data Supplement).
Management Strategy
A total of 488 patients (64.4%) were referred to our institution from other centers after coronary angiography (CA), whereas the remaining 270 patients (35.6%) were catheterized in our institution. Among patients operated on within 24 hours (group A), 68 (51.1%) and 65 (48.9%) underwent CA at the referral center and our institution, respectively. Correspondingly, 114 (59.4%) and 78 (40.6%) patients in group B and 306 (70.7%) and 127 (29.3%) patients in group C underwent CA before referral and after admission to our institution. Patients with NSTEMI referred to our department are by default already considered unsuitable for PCI by cardiologists or the heart team, most frequently because of unfavorable coronary anatomy and in some situations because of a complicated or an unsuccessful PCI. As per our departmental policy, urgent or emergent CABG is indicated in patients with ongoing ischemia (refractory angina pectoris, dynamic electrocardiographic changes, persistent rise in levels of cardiac enzymes, significant regional wall motion abnormalities on echocardiography), hemodynamic instability, cardiogenic shock, refractory ventricular arrhythmias, and complicated PCI. We do not hesitate to operate on such patients without discontinuing clopidogrel. In patients on ticagrelor or prasugrel, we prefer to discontinue these drugs 5 and 7 days before CABG, respectively, hemodynamics and ischemic signs and symptoms permitting. All possible measures to maintain stable hemodynamics are also implemented to help tide the patient over this waiting period. In case of unfavorable coronary anatomy (severe unprotected left main disease [LMD] or diffuse triple-vessel disease), bridging antiplatelet therapy with intravenous glycoprotein IIb/IIIa inhibitors is used for 2 to 3 days before surgery after discontinuation of ticagrelor or prasugrel. However, the presence or development of intractable hemodynamic instability or cardiogenic shock is an indication for immediate surgery regardless of the time duration after discontinuation of P2Y 12 inhibitor therapy.
The CABG technique and choice of conduits used were at the discretion of the operating surgeon. Our departmental preference is off-pump CABG in hemodynamically stable patients and beating-heart on-pump CABG (without aortic clamping) in unstable patients.
14 Young patients (<70 years of age) usually receive complete arterial revascularization. Intravenous acetylsalicylic acid is administered 6 hours postoperatively in patients in whom bleeding is not a concern. P2Y 12 inhibitors are added the following day, and the preoperative medication usually is continued, unless the surgeon prefers otherwise.
Postoperative Outcomes
HM was our primary outcome. Secondary outcomes were 5-year survival and freedom from major adverse cardiac and cerebrovascular events (MACCEs) defined as the composite of all-cause mortality, MI, stroke, and repeat revascularization. Follow-up was obtained by personal or phone contact with patients and family members and mailed questionnaires, with supplemental information supplied by family physicians and referring cardiologists. The closing interval, that is, the time period during which all surviving patients included in the analysis were exclusively followed up, for the present study was January through October 2014. Overall, 50 patients were lost to follow-up, resulting in 93.4% completeness of follow-up. were submitted to a logistic regression model by stepwise selection to determine the independent predictors of HM, which are expressed as odds ratios and 95% confidence intervals (CIs). Multicollinearity was assessed with linear regression analysis in which a variance inflation factor >4.0 indicated potential intercorrelation among variables. If multicollinearity existed, correlated variables were combined into a single variable, or 1 variable from a set of correlated variables was selected for the multivariate analysis. Model discrimination was assessed by the area under the receiver-operator characteristic curve and calibration by the Hosmer-Lemeshow goodness-of-fit statistic. Event-free survival and freedom from MACCEs were calculated by Kaplan-Meier methods, with the 95% CI and statistical difference in survival curves between groups determined by the log-rank test. To account for the 50 patients lost to follow-up during the study period, we tried to identify the effect of patient withdrawal on survival by assuming that these patients were dead at the last available contact date. Independent predictors of midterm survival were determined with Cox proportional hazards analysis. Covariates were included on the basis of clinical relevance or significance of univariable association. Model assessment was performed by calculation of the likelihood χ 2 statistic by comparing the deviance (−2 times log likelihood) of our model, with all of the specified covariates, against the model with all covariates dropped. To evaluate the impact of timing of CABG on in-hospital and late mortality, groups A and B were forced into the multivariate and Cox regression models, with group C as the reference. Values of P<0.05 were considered statistically significant.
Results
Preoperative Data
Of the 758 patients undergoing CABG within 21 days of NSTEMI, 133 underwent surgery within the first 24 hours of NSTEMI symptom onset (group A), 192 underwent surgery between 24 to 72 hours after symptom onset (group B), and 433 underwent surgery between 4 to 21 days after symptom (group C). Group A patients had a significantly higher risk profile (logistic EuroSCORE) than group B and C patients because of a greater prevalence of shock patients and lower mean left ventricular ejection fraction requiring more inotropic and intraaortic balloon support (Table 1) . Furthermore, the total CK, CK-MB, and serum lactate levels before surgery were higher in group A patients. Almost 40% of patients received P2Y 12 inhibitors in addition to acetylsalicylic acid and intravenous unfractionated heparin, which did not differ between groups.
When the 43 shock patients were excluded, groups A, B, and C had 119, 177, and 419 patients, respectively (Table I in the online-only Data Supplement). Despite the exclusion of shock patients from the analysis, the overall acuity of patients in group A remained higher than in the other 2 groups.
Intraoperative Data
The intraoperative data are given in Table 2 . Off-pump and on-pump CABG techniques were evenly distributed between the 3 groups. Group A and B patients frequently underwent on-pump CABG without aortic clamping. The left anterior descending region was the most commonly revascularized territory, followed by the circumflex and right coronary artery regions. Fewer than one-fifth of patients underwent incomplete revascularization, with a similar incidence in the 3 groups. Exclusion of shock patients did not alter the above trends (Table II in 
In-Hospital Outcomes
The HM was 5.1% (39 patients) for all patients (Table 3 ) and 4.6% (33 patients) when shock patients were excluded from the analysis ( Table III in the online-only Data Supplement). It did not differ between the 3 groups, even after exclusion of shock patients. Of the 39 hospital deaths, 25 were due to low-output cardiac failure and 2 each were due to hemorrhagic shock, multiorgan system failure, respiratory insufficiency, gastrointestinal bleeding, and mesenteric ischemia. One patient died of an iatrogenic type A aortic dissection. The exact cause of death was unknown in 2 patients. Development of low cardiac output syndrome and the use of artificial cardiopulmonary support were significantly higher in group A. Postoperative complications such as cerebrovascular accidents, respiratory insufficiency, reintubations, and tracheostomies were more likely to occur in group B patients. Re-exploration for bleeding was similar between groups, but transfusion of blood products such as red blood cells, platelets, and fresh-frozen plasma concentrates was more frequently encountered in group B patients, who also required longer respiratory support and had longer intensive care unit and hospital stays. Postoperative morbidity revealed a similar trend even after the exclusion of shock patients from the analysis (Table III in 
Predictors of HM
The independent predictors of HM were LMD and grade 3 to 5 renal insufficiency (Table 4) . Preoperative cardiogenic shock, which appeared to be significantly associated with HM on univariable analysis (odds ratio, 3.3; 95% CI, 1.3-8.5; P=0.01), was not found to be an independent predictor on multivariate analysis. When groups A and B were forced into the multivariate regression model with group C used as reference, neither was found to be a significant predictor of HM. Use of P2Y 12 inhibitors until surgery was found to have a protective effect against HM (Table 4) .
Follow-Up
The 1-and 5-year survival for all patients was 86.2±1% and 73.1±2%, respectively, and the freedom from MACCEs was 85.0±1% and 65.1±2%, respectively. The 1-and 5-year groupwise survival for all patients was 86.3±3% and 78.2±4%, 82.5±3% and 63.6±5%, and 87.8±2% and 75.4±3% for groups A, B, and C, respectively (log-rank P=0.06; Figure 1A ). The corresponding freedom from MACCEs was 83.3±3% and 70.7±5%, 80.9±3% and 58.8±5%, and 87.3±2% and 66.1±3%, respectively (log-rank P=0.1; Figure 2A ).
The relationship with survival between the 3 groups remained the same (log-rank P=0.1), regardless of whether all patients lost to follow-up were assumed to be dead or alive ( Figure I in the online-only Data Supplement). On exclusion of shock patients from the analysis, the 1-and 5-year survival was 87.4±1% and 74.8±2%, respectively, and the freedom from MACCEs was 86.1±1% and 66.4±2%, respectively. The groupwise 1-and 5-year survival was 88.1±3% and 79.0±5%, 83.3±2% and 67.6±5%, and 88.9±1% and 76.5±3% for groups A, B, and C, respectively (log-rank P=0.1; Figure 1B ). The corresponding freedom from MACCEs was 84.7±3% and 70.6±5%, 81.6±2% and 62.2±5%, and 88.4±1% and 67.0±3%, respectively (log-rank P=0.1; Figure 2B ). The groups showed no difference in freedom from MI.
A total of 118 patients died during follow-up. Cox regression analysis including the entire cohort revealed incremental age (hazard ratio, 1.04; 95% CI, 1.01-1.06; P=0.001), LMD (hazard ratio, 1.50; 95% CI, 1.07-2.11; P=0.02), and renal insufficiency (hazard ratio, 1.75; 95% CI, 1.19-2.56; P=0.004) to be independent predictors of long-term mortality. Neither group A nor B was found to predict late mortality. Exclusion of shock patients did not alter the above findings (Table 5) .
Discussion
The present study represents the largest and most comprehensive single-center report analyzing the impact of time interval between onset of NSTEMI and CABG on both early and long-term outcomes after surgery performed during the same hospital admission. This study is unique in that it concerns exclusively patients with NSTEMI treated with early surgery in the contemporary era. The overall HM was 5.1% and did not differ according to timing of CABG after symptom onset. Additionally, the groupwise HM was much lower than the EuroSCORE-predicted operative mortality, even after compensation for its overestimation by the latter. Senanayake and colleagues 15 similarly reported that CABG for NSTEMI during the same hospital admission is associated with a low mortality risk and significantly better survival than that predicted by the Global Registry of Acute Coronary Events (GRACE) score. We noted that patients operated on within 24 hours of NSTEMI (group A) had a much higher risk profile compared with those undergoing delayed surgery (groups B and C), even when shock patients were excluded from the analysis. In addition, group A and B patients had significantly higher CK and CK-MB levels than group C patients. Furthermore, the number of patients in whom the indication for early CABG was persistent rise in CK and CK-MB levels was similar in groups A and B but significantly higher than in group C. These findings probably suggest that significantly greater numbers of patients in groups A and B had evolving infarcts. Postoperative respiratory failure and cerebrovascular accidents occurred more frequently in group B patients, who also had a greater requirement for new dialysis and tracheostomy, longer ventilation times, and longer intensive care unit and hospital stays. It was evident from our series that most patients in group B (59.4%) were referred from other centers after undergoing CA. This trend toward poorer outcomes could be attributed to delayed surgery in some group B patients who should have been revascularized earlier, thus resulting in a longer period of untreated infarct, hemodynamic compromise, and hypoperfusion. One Values are expressed as mean±SD when appropriate. CK indicates creatine kinase; ECMO, extracorporeal membrane oxygenation; FFP, fresh-frozen plasma; HM, in-hospital mortality; and ICU, intensive care unit. Groups A, B, and C: patients undergoing CABG within 24, 24 to 72, and >72 hours after non-ST-segment-elevation myocardial infarction, respectively could thus speculate that earlier CABG within the first few hours after NSTEMI might have averted these complications in such patients. Few contemporary and some older reports have also reflected our findings. Parikh et al 6 reported similar composite outcomes of death, MI, congestive heart failure, or cardiogenic shock among patients undergoing early (<48 hours) versus late (≥48 hours) CABG for NSTEMI. Similarly, Braxton and coworkers 9 found that mortality did not differ between patients undergoing CABG <48 hours, 3 to 5 days, and 6 to 42 days from admission. The Spokane group published a report on surgical revascularization of 261 patients within 24 hours of nontransmural MI with an HM of 3.1% and concluded that recurrent MI and mortality are substantially reduced by immediate total revascularization. 16 On the contrary, some investigators argue that performing CABG within the first 3 days of NSTEMI is associated with increased risk of mortality. Lee at al 8 found a decreasing trend in HM with increasing time interval between CABG and MI: 11.8%, 9.5%, and 2.8% (P<0.001 for all values) for <6 hours, 6 hours to 1 day, and >1 day, respectively. An exclusive analysis of patients with NSTEMI revealed that CABG within 6 hours of MI predicted HM, whereas CABG between 6 to 23 hours did not. In our study, neither group A nor B predicted HM, which was marginally lower (6.0%) in our series than theirs (6.3%). A review of the California Discharge data by Weiss and coworkers 17 also reported a significantly higher mortality rate of 5.6% among patients undergoing early CABG (0-2 days) compared with 3.6% for late CABG (>3 days) with a peak mortality of 8.2% on day 0 after acute MI. Of note, the above-mentioned studies included both STEMI and NSTEMI patients, and the latter analysis had a lower percentage of subendocardial infarcts (45% versus 61%; P<0.001) in the early CABG group. Furthermore, it is very difficult to confirm whether hospitals and surgeons contributing to such registries observed similar standards and protocols, particularly the diagnosis of NSTEMI, which could be challenging.
The superior results of emergent CABG (group A) observed in the present study can be attributed to several factors. Because NSTEMI is characterized by nontransmural necrosis, early revascularization, even in hemodynamically stable patients with evidence of ongoing ischemia, can prevent progression to transmurality, thus confining infarct expansion. This can restrict ventricular remodeling and maintain left ventricular function, sometimes also leading to improved ejection fraction, 18 which translates to better outcomes. In addition, group A patients had a higher risk profile and had more elevated levels of cardiac biomarkers. Two large meta-analyses including large RCTs comparing early invasive versus conservative strategies for NSTE-ACS revealed that higher-risk patients with elevated cardiac biomarker levels at baseline benefited more from routine invasive intervention, 19 with a reduction in the combined end point of MI and death seen only in patients with high-risk features, including those with elevated troponin levels. 20 Furthermore, the occurrence of postoperative MI was extremely low in the present study, occurring most in patients operated after 72 hours of NSTEMI. This is in stark contrast to a multicenter RCT in which NSTE-ACS patients randomized to immediate PCI developed significantly more MI compared with those undergoing PCI 23 to 48 hours after NSTE-ACS (60% versus 38%; relative risk, 1.6; P=0.005). 21 This could be due to microemboli from the atherosclerotic plaque, thrombus particles disrupted or formed during angioplasty, or thrombotic side-branch occlusions, which occur very infrequently during surgery. Moreover, >50% of operations were performed offpump, and a third of the on-pump surgeries (hemodynamically unstable patients) were performed without ischemic arrest in our study. Our group has previously shown that beating-heart CABG is associated with better in-hospital and long-term outcomes in patients with ACS 14 because it avoids global ischemia in an already ischemic heart. Additionally, off-pump CABG reduces the systemic inflammatory response that is commonly observed after on-pump CABG. Finally, tremendous progress in anesthetic and perioperative management of patients undergoing cardiac surgery is also one of the key factors that contribute immensely to improved outcomes.
Because of the paucity of evidence concerning longterm outcomes after CABG in patients with NSTEMI, we performed an exhaustive analysis of our 5-year follow-up data. The overall 5-year survival of patients (73.1±2%; 74.8±2% on exclusion of shock patients) in our series was lower than that reported by Selinger et al 16 (6 .5% mortality at 8 years). The latter publication (>30 years ago) is the only other study besides ours that exclusively reported long-term outcomes of CABG for NSTEMI. However, the mean age of patients was 58 years (70±10 years in our series), and the prevalence of LMD was only 11% (almost 40% in our study), which is important considering the fact that both incremental age and LMD independently predicted late mortality in our series. Although other preoperative variables were not mentioned in this report, most studies in the 1970s and early 1980s included patients with single-or double-vessel disease with a lower risk profile.
The groupwise analysis revealed a nonsignificant trend (P=0.06) toward a lower survival in patients operated on between 24 to 72 hours after NSTEMI ( Figure 1A) . A similar trend (P=0.06) was observed when group A was compared separately with group B. However, when HM was excluded from the analysis, group A patients were found to have significantly better 5-year survival than group B patients (P=0.02), a trend that was also observed on comparison of group B and C patients (P=0.03; P=0.008 on exclusion of HM). Worst survival in group B patients could be due to either a delay in surgery resulting in continuing myocardial damage or a larger infarct or territory at risk from the outset, both of which are associated with postoperative complications such as low-output syndrome, acute renal failure, respiratory insufficiency, and cardiac arrhythmias, which in turn negatively affect survival. The fact that LMD was an independent predictor of both HM and late mortality in our study could further justify the above statement because patients with LMD have more susceptible myocardial area, and delaying surgery in these patients could potentially put them at an increased risk of developing cardiogenic shock and eventually death. Almost half the patients in cardiogenic shock in our series had LMD. The trend in freedom from MACCEs mirrored those of survival (Figure 2) because it was driven chiefly by all-cause mortality. At follow-up, 11 and 18 patients developed MI and stroke, respectively, and 19 patients required repeat revascularization. One could conclude from the above observations that earlier surgical revascularization (<24 hours) translates to better long-term outcomes. Hence, emergent CABG should be contemplated in hemodynamically unstable patients or those presenting with the smallest hint of continuing ischemia, even if they are hemodynamically stable. Our findings are also reflected by a meta-analysis of 3 large RCTs comparing routine and selective invasive strategy in patients with NSTEMI, which showed 2.0% to 3.8% absolute reductions in cardiovascular death or MI in the low-and intermediate-risk groups and an 11.1% absolute risk reduction in highest-risk patients. 22 One of the major concerns surgeons have in performing emergent CABG after acute MI is the increased risk of bleeding resulting from the liberal use of "upstream" antiplatelet medications, which should be initiated as soon as possible after the diagnosis of ACS is made 10 to avoid ischemic complications. Our study also found that administration of P2Y 12 inhibitors in addition to aspirin in patients with NSTEMI until surgery is protective against HM (odds ratio, 0.3; 95% CI, 0.1-0.8; P=0.01; Table 4 ). In the present series, almost 40% of patients received dual antiplatelet therapy until the day of surgery, with no difference between groups ( Table 3 ). The rate of re-exploration for bleeding also did not differ between groups. However, group B patients received significantly greater numbers of red blood cell, platelet, and plasma transfusions than group A and C patients. Nevertheless, when we analyzed the whole cohort of patients with NSTEMI with regard to continuation of P2Y 12 inhibitors until surgery, we found no difference in the use of red blood cells (68.3% versus 69.3%), recently reported significantly higher rate of bleeding complications when clopidogrel or ticagrelor was discontinued 0 to 1 day before surgery as opposed to 5 days before CABG. The overall re-exploration rate was 6.9% and 7.5% for the clopidogrel and ticagrelor groups, respectively, and 11% and 23% when the medications were discontinued 0 to 1 day before surgery. The mean number of red blood cell transfusions was 5.9±7.2 and 4.3±4.6 when clopidogrel was stopped 0 to 1 day and 2 to 4 days before surgery, respectively. These observations on postoperative bleeding are much worse than those in our study (Table 3) , probably because of the higher number of off-pump CABGs, which has been shown to be associated with reduced blood loss. 24, 25 In our series, significantly fewer patients undergoing off-pump CABG received erythrocyte, platelet, or fresh-frozen plasma transfusions (59.3%, 25.3%, and 27.2%, respectively) compared with those undergoing on-pump beating-heart (83.5%, 44.9%, and 51.2%, respectively) or arrested-heart (76.2%, 25.4%, and 28.2%, respectively) CABG (P<0.0001). Furthermore, re-exploration for bleeding was the lowest after off-pump CABG, although this was not significantly different from that after both on-pump techniques (2.6%, 3.9%, and 2.9%, respectively; P=0.7). This may be due to preserved coagulation and platelet function, reduced destruction of red blood cells and platelets, and decreased hemodilution by avoiding cardiopulmonary bypass and an attenuated inflammatory response in the off-pump setting. Another large study by Ebrahimi and colleagues 26 concluded that clopidogrel administration before catheterization in patients with NSTE-ACS requiring CABG is associated with significantly fewer 30-day adverse ischemic events without a significant increase in major bleeding compared with withholding clopidogrel until after angiography. Our findings are suggestive of the fact that continuing dual antiplatelet therapy until surgery in patients with NSTEMI renders a protective effect against in-hospital death, probably by reducing further ischemic events, and does not increase the risk of bleeding after emergent CABG compared with delayed surgery. However, caution should be exercised in the interpretation of our findings because the type of P2Y 12 inhibitors is not mentioned in our database.
Study Limitations
The present study is a retrospective analysis and therefore is subject to the inherent weaknesses of such an analysis. The 3 groups are not similar with respect to preoperative characteristics because each time interval represents a phase in the natural course of NSTEMI. However, the essential factor is to determine whether the decision to perform CABG at a specific moment, which allegedly was justified at the time, was appropriate. This can be achieved only by comparing groups of patients formed according to designated time intervals between symptom onset and surgery. Another drawback is the inability of our study to capture the patients who died or worsened clinically while waiting for surgery, especially those referred to us from peripheral hospitals. Hence, retrospectively predicting outcomes in patients, had surgery been delayed, is not possible from our study. Furthermore, whether stable patients without evidence of ongoing ischemia should also undergo emergent CABG cannot be deduced from the present study. An RCT could resolve this dilemma. However, no prospective, randomized studies of the appropriate timing of surgery after NSTEMI exist at the present time. Therefore, studies such as ours currently offer the best possible evidence.
Conclusions
Our study shows that emergent CABG within the first 24 hours after NSTEMI can be performed with an HM rate, a bleeding complication rate, and long-term outcomes similar to those of patients undergoing surgery after 3 days, despite a higher risk profile. CABG performed between 24 to 72 hours after NSTEMI showed a nonsignificant trend toward poorer longterm outcomes. Hence, we recommend emergent CABG not only in patients with a high risk profile, hemodynamic instability, or definitive evidence of ongoing ischemia but also in other low-to intermediate-risk patients with the slightest indications of ischemia, because delaying surgery may sometimes result in worse outcomes with increased use of resources. The heart team would be appropriate in determining a balanced approach in such patients. Continuation of dual antiplatelet therapy until surgery protects against HM, whereas patients with preoperative renal insufficiency and LMD have an increased risk of early and late mortality.
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